Bharat Parenterals Q2 FY27 Consolidated Results And Growth Strategy
Bharat Parenterals Ltd · Investor Presentation · 29 Oct 2026, 10:44 pm
Bharat Parenterals Q2 FY27 Consolidated Results And Growth Strategy Bharat Parenterals reported consolidated Q2 FY27 revenue of ₹136.3 Cr (+110.9% YoY, +45.4% QoQ), with operating EBITDA surging to ₹23.6 Cr (17.3% margin) and PAT reaching ₹11.8 Cr (₹9.4 Cr to owners), driven by subsidiary Innoxel's turnaround to ₹5.4 Cr PAT and ₹44.5 Cr revenue (+253.1% YoY). BPL Standalone generated ₹78.6 Cr revenue (+88.4% YoY) with ₹117.83 Cr in orders as of 30th Sep'26. Additionally, the company approved a ₹139 Cr preferential issue to fund expansion, including Varenyam Bio’s revised ₹300 Cr biologics CDMO facility.
Original exchange filing (PDF)
More announcements from Bharat Parenterals Ltd
- Intimation for receipt of Establishment Inspection Report from US FDA by Innoxel Lifesciences Pvt Ltd., a subsidiary company of Bharat Parenterals Limited. · 05 Nov 2026
- Transcript of Earnings Conference Call of Q2FY27. · 02 Nov 2026
- Audio Recording of Q2FY27 Earnings Conference Call. · 30 Oct 2026
- Un-Audited Standalone and Consolidated Financial Results For the Quarter and Half Year Ended On September 30, 2026. · 29 Oct 2026
- Outcome of the Meeting of the Board of Director of Bharat Parenterals Limited held on October 29, 2026 · 29 Oct 2026
- Approval of Preferential Issue by Shareholders of the Company through EGM Held on October 23, 2026. · 25 Oct 2026
- Revised Voting Result · 25 Oct 2026
- Approval of Preferential Issue by shareholders of the company through EGM held on October 23, 2026. · 24 Oct 2026
